SCHEMBL18655340

SCHEMBL18655340

CCOC(=O)CC1CN(C(=O)OC(C)(C)C)CC(CC(=O)OCC)N1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.44
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
SRC P12931 8/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NAMPT P43490 1/20 0.36
ADORA1 P30542 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25764344 0.94 NR1H2 (0.40) NR1H2CHRM2CHRM1CHRM3SRC
SCHEMBL23555938 0.89 NR1H2 (0.44) NR1H2SRCUSP2SMN1; SMN2L3MBTL1
SCHEMBL22075650 0.84 CHRM2 (0.42) CHRM2CHRM1CHRM3SRCSMN1; SMN2
SCHEMBL1661739 0.84 NR1H2 (0.51) NR1H2USP2SMN1; SMN2L3MBTL1NAMPT
SCHEMBL21722174 0.82 PARP1 (0.39) NR1H2SRCUSP2SMN1; SMN2ADORA1
SCHEMBL31401101 0.81 NR1H2 (0.46) NR1H2USP2SMN1; SMN2L3MBTL1NAMPT
SCHEMBL30277096 0.81 NR1H2 (0.46) NR1H2USP2SMN1; SMN2L3MBTL1NAMPT
SCHEMBL3897900 0.80 SRC (0.38) NR1H2SRCUSP2SMN1; SMN2ALDH1A1
SCHEMBL22075687 0.80 CHRM2 (0.38) CHRM2CHRM1CHRM3SRCSMN1; SMN2
SCHEMBL38663334 0.80 CETP (0.35) NR1H2CHRM2CHRM1CHRM3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10167283-B2 β-lactamase inhibitors and uses thereof SUANZHU PHARMA CO., LTD. (CN) 2019-01-01 US disclosed
US-10167283-B2 β-lactamase inhibitors and uses thereof SUANZHU PHARMA CO., LTD. (CN) 2019-01-01 US disclosed
US-20180148448-A1 ß-LACTAMASE INHIBITORS AND USES THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2018-05-31 US disclosed
US-20180148448-A1 ß-LACTAMASE INHIBITORS AND USES THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2018-05-31 US disclosed
US-20180148448-A1 ß-LACTAMASE INHIBITORS AND USES THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2018-05-31 US disclosed
EP-3281942-A1 B-LACTAMASE INHIBITOR AND APPLICATION THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2018-02-14 EP disclosed
EP-3281942-A1 B-LACTAMASE INHIBITOR AND APPLICATION THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2018-02-14 EP disclosed
WO-2017167218-A1 ANTIBACTERIAL COMPOSITION AND USE THEREOF 山东轩竹医药科技有限公司 2017-10-05 WO disclosed
WO-2017045510-A1 Β-LACTAMASE INHIBITOR AND APPLICATION THEREOF 山东轩竹医药科技有限公司 2017-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167283-B2 β-lactamase inhibitors and uses thereof MGAM, LCT, ALPI NR1H2 1027/4885CHRM2 1055/4885CHRM1 609/4885
US-20180148448-A1 ß-LACTAMASE INHIBITORS AND USES THEREOF MGAM, LCT, ALPI NR1H2 1006/4885CHRM2 1084/4885CHRM1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.